1.

Record Nr.

UNINA9910786043603321

Autore

Axelrod C. Warren

Titolo

Engineering safe and secure software systems / / C. Warren Axelrod

Pubbl/distr/stampa

Boston : , : Artech House, , [2013]

[Piscataqay, New Jersey] : , : IEEE Xplore, , [2012]

ISBN

1-60807-473-0

Descrizione fisica

1 online resource (349 p.)

Collana

Artech House information security and privacy series

Disciplina

620.001/171

Soggetti

Software engineering

Systems engineering

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references and index.

Nota di contenuto

1. Introduction -- 2. Engineering Systems -- 3. Engineering Software Systems -- 4. Engineering Secure and Safe Systems, Part 1 -- 5. Secure and Safe Systems, Part 2 -- Secure and Safe Systems, Part 2 -- 6. Software Systems Security and Safety Risk -- 7. Software System Security and Safety Metrics -- 8. Software System Development Processes -- 9. Secure SSDLC Projects in Greater Detail -- 10. Safe SSDLC Projects in Greater Detail -- 11. The Economics of Software Systems' Safety and Security -- Appendices.

Sommario/riassunto

"This first-of-its-kind resource offers a broad and detailed understanding of software systems engineering from both security and safety perspectives. Addressing the overarching issues related to safeguarding public data and intellectual property, the book defines such terms as systems engineering, software engineering, security, and safety as precisely as possible, making clear the many distinctions, commonalities, and interdependencies among various disciplines. You explore the various approaches to risk and the generation and analysis of appropriate metrics. This unique book explains how processes relevant to the creation and operation of software systems should be determined and improved, how projects should be managed, and how products can be assured. You learn the importance of integrating safety and security into the development life cycle. Additionally, this practical volume helps identify what motivators and deterrents can be put in



place in order to implement the methods that have been recommended."

2.

Record Nr.

UNINA9910779772803321

Autore

Sherman Phillip Michael

Titolo

Babel's Tower translated [[electronic resource] ] : Genesis 11 and ancient Jewish interpretation / / by Phillip Michael Sherman

Pubbl/distr/stampa

Leiden ; ; Boston, : Brill, 2013

ISBN

90-04-24861-7

Descrizione fisica

1 online resource (377 p.)

Collana

Biblical interpretation series ; ; vol. 117

Disciplina

222/.110609

Soggetti

Babel, Tower of

Rabbinical literature - History and criticism

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references and index.

Nota di contenuto

Front Matter -- Interpretation as Translation or Exegesis and Historical Hermeneutics -- Introduction to Part I -- Return to Babel: Reading without the Canon -- Reading Babel Backwards. Canonical Foundations for Exegetical Expansion -- Introduction to Part II -- The Holy Language in the Book of Jubilees: The Tower of Babel and the Eclipse of Sacred Tradition -- Pseudo-Philo’s Biblical Antiquities: Echoes of the Tower -- Josephus and the Influence of Anxiety: Colonizing the Tower and the Politics of Dispersion -- Translated to Heaven: The Tower of Babel and Third (Greek) Baruch -- The Inner Tower: Philo and the Translation of Cultures -- Introduction to Part III -- A Just Translation: Reading the Rabbinic Babel in Genesis Rabbah -- Conclusion -- Bibliography -- Indexes.

Sommario/riassunto

In Babel's Tower Translated , Phillip Sherman explores the narrative of Genesis 11 and its reception and interpretation in several Second Temple and Early Rabbinic texts (e.g., Jubilees, Philo, Genesis Rabbah). The account of the Tower of Babel (Genesis 11:1-9) is famously ambiguous. The meaning of the narrative and the actions of both the human characters and the Israelite deity defy any easy explanation. This work explores how changing historical and hermeneutical realities



altered and shifted the meaning of the text in Jewish antiquity.

3.

Record Nr.

UNINA9910781469203321

Titolo

Current issues in Romance languages : selected papers from the 29th Linguistic Symposium on Romance Languages (LSRL), Ann Arbor, 8-11 April 1999 / / edited by Teresa Satterfield, Christina Tortora, Diana Cresti

Pubbl/distr/stampa

Amsterdam ; ; Philadelphia : , : J. Benjamins Pub., , 2002

©2002

ISBN

1-283-31219-0

9786613312198

90-272-7543-2

Descrizione fisica

1 online resource  (vi, 403 pages)

Collana

Amsterdam studies in the theory and history of linguistic science. Series IV, Current issues in linguistic theory, , 0304-0763 ; ; v. 220

Altri autori (Persone)

SatterfieldTeresa <1965->

TortoraChristina

CrestiDiana

Disciplina

440

Soggetti

Romance languages

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Nota di bibliografia

Includes bibliographical references and index.

Nota di contenuto

CURRENT ISSUES IN ROMANCE LANGUAGES; Editorial page; Title page; Copyright page; Table of contents; PREFACE; ON BECOMING A CLITIC: THE  PRENOMINAL POSSESSIVE IN ROMANCE; 0. Introduction; 1. Latin roots; 2. Development from Latin; 2.1 Old French; 2.2 Old Spanish; 2.3 Italian; 3. Syntactic Representation; 4. Conclusion; REFERENCES; PRIMARY STRESS IN SPANISH; 0. Introduction; 1. Data; 2. Test; 3. Analysis; 3.1 Lexical patterns; 3.2 Quantity sensitivity; 3. 3 Falling diphthongs; 3.4 A process in change; 4. Ternary Feet; 5. Conclusion; REFERENCES; SPANISH CLAUSES WITHOUT COMPLEMENTIZER

1. Introduction 2. Spanish clauses without complementizer; 3. On the presence or absence of the CP projection; 3.1 Topicalization; 3.2 Wh-extraction; 4. On the impossibility of a pre-verbal subject in



complementizerless clauses; 5. Conclusion; REFERENCES; ON THE NATURE OF BARE NOUNS IN HAITIAN CREOLE; 1. Introduction; 2. Theoretical Background; 3. The properties of Haitian Creole bare Nouns; 4. HC bare nouns in Chierchia's typology; 5. Evidence for a null determiner in HC; 6. The syntax and semantics of the Haitian Creole null D°; REFERENCES; TOWARDS A SYNTAX OF ADULT ROOT INFINITIVES

0. Introduction 1. Syntactic properties; 1.1 Adverb placement; 1.2 Left periphery; 1.3 Clausal structure; 2. Some differences; 2.1 Temporal interpretation; 2.2 Topic constructions; 2.3 Subject properties; 2.4 Infinitival raising; 3. Syntactic analysis; 4. Conclusion; REFERENCES; RE-EXAMINING SPANISH 'RESYLLABIFICATION'; 1. Introduction; 2. Data; 3. The Status of Spanish Prefixes; 4. A Theoretical Analysis of Spanish Syllabification; 5. Previous Analyses and Their Shortcomings; 6. Conclusion; REFERENCES; ON PREVERBAL SUBJECTS IN SPANISH; 0. Introduction; 1. Spanish preverbal subjects

2. Evidence that preverbal subjects are not in topic position 3. Focus/wh-phrases; 4. Evidence that preverbal subjects are not in focus/wh- position; 5. Towards a solution; 6. Conclusions; REFERENCES; THE SEMANTICS OF SPANISH FREE RELATIVES; 1. The morphological encoding of quantificational force; 2. Indefinite FRs; 3. Definite vs. universal FRs; 4. The semantic interpretation of FRs; REFERENCES; SPLIT SUBJECT PRONOUN PARADIGMS: FEATURE GEOMETRY AND UNDER SPECIFICATION; 0. Introduction; 1. Linguistic Atlas Data; 2. How many parameters?; 3. Feature Geometry; 4.Underspecification

4.1 The tu ~ vous split 5. Splitting the Geometry; 6. Conclusion; REFERENCES; LOCATIVE INVERSION, PP TOPICALIZATION AND THE EPP; 0. Introduction; 1. The transitivity restriction in English; 2. Agr as [+D] head in Spanish; 3. Locative subjects vs. fronted locative PPs in Spanish; 4. PP fronting in Italian; 5. Conclusion; REFERENCES; CONTRAST MAINTENANCE AND INTERVOCALIC STOP LENITION IN SPANISH AND PORTUGUESE: WHEN IS IT ALRIGHT TO LENITE?; 0. Introduction; 1. Lenition Processes; 2. The phonetic implementation of intervocalic stops in Spanish and Portuguese; 3. Experimental design; 4. Results; 5. Conclusions

Sommario/riassunto

This book presents an enlightening collection of papers contributing to theoretical discussions across many topics within the study of Romance Languages and Linguistics. The work originates from the 29th Linguistic Symposium on Romance Languages held in 1999 at the University of Michigan-Ann Arbor, although only a small subpart of the proceedings papers are included in this volume. The selected papers have been reworked for the current publication.



4.

Record Nr.

UNINA9910839791803321

Autore

Picardi, Filippo

Titolo

Morale e filosofia della morale in Erminio Juvalta / Filippo Picardi

Pubbl/distr/stampa

Milano, : Marzorati, copyr. 1978

Descrizione fisica

220 p. ; 24 cm

Collana

Pubblicazioni dell'Istituto di filosofia, Facoltà di magistero dell'Università di Genova ; 24

Disciplina

171

Locazione

FLFBC

Collocazione

DAM A70 PICF 01

Lingua di pubblicazione

Italiano

Formato

Materiale a stampa

Livello bibliografico

Monografia

5.

Record Nr.

UNICAMPANIAVAN00256954

Autore

Hackett, Paul M. W <1960->

Titolo

An Introduction to Using Mapping Sentences / Paul M. W. Hackett, Katelyn Lustig

Pubbl/distr/stampa

Cham, : Palgrave Macmillan, 2021

Descrizione fisica

XIX, 105 p. ; 24 cm

Altri autori (Persone)

Lustig, Katelyn

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia



6.

Record Nr.

UNINA9911020083103321

Autore

Corey E. J

Titolo

Molecules Engineered Against Oncogenic Proteins and Cancer : Discovery, Design, and Development

Pubbl/distr/stampa

Newark : , : John Wiley & Sons, Incorporated, , 2023

©2023

ISBN

9781394207145

139420714X

9781394207091

1394207093

Edizione

[1st ed.]

Descrizione fisica

1 online resource (391 pages)

Altri autori (Persone)

WuYong-Jin

Soggetti

Protein kinases - Inhibitors

Oncogenes

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Nota di contenuto

Cover -- Title Page -- Copyright -- Contents -- Preface -- Chapter 1. Introduction -- 1.1 Types of Protein Kinases -- 1.2 Protein Kinase Domains -- 1.3 ATP-Binding Site -- 1.4 Types of Kinase Inhibitors -- 1.5 Brief History of Small-molecule kinase Inhibitors -- 1.6 Peak 12-Month Sales for Leading Kinase Inhibitors -- 1.7 Approved Kinase Inhibitors -- Chapter 2. BCR-ABL Inhibitors -- 2.1 Imatinib* -- 2.2 Nilotinib* -- 2.3 Dasatinib* -- 2.4 Bosutinib* -- 2.5 Ponatinib* -- 2.6 Olvermbatinib** -- 2.7 Asciminib* -- Chapter 3. BTK Inhibitors -- 3.1 Ibrutinib* -- 3.2 Acalabrutinib* -- 3.3 Zanubrutinib* -- 3.4 Tirabrutinib** -- 3.5 Orelabrutinib** -- Chapter 4. EGFR/HER Family Inhibitors -- 4.1 Gefitinib* -- 4.2 Erlotinib * -- 4.3 Icotinib** -- 4.4 Afatinib* -- 4.5 Dacomitinib* -- 4.6 Osimertinib* -- 4.7 Mobocertinib* -- 4.8 Lapatinib* -- 4.9 Tucatinib* -- 4.10 Neratinib* -- Chapter 5. VEGFR/Multikinase Inhibitors -- 5.1 Sorafenib* -- 5.2 Regorafenib* -- 5.3 Sunitinib* -- 5.4 Pazopanib* -- 5.5 Axitinib* -- 5.6 Nintedanib* -- 5.7 Apatinib** -- 5.8 Lenvatinib* -- 5.9 Tovozanib* -- Chapter 6. CDK4/6 Inhibitors -- 6.1 Palbociclib* -- 6.2 Ribociclib* -- 6.3 Abemaciclib* -- 6.4 Trilaciclib* -- Chapter 7. JAK Inhibitors -- 7.1



Tofacitinib* -- 7.2 Baricitinib* -- 7.3 Peficitinib** -- 7.4 Upadacitinib* -- 7.5 Delgocitinib** -- 7.6 Filgotinib** -- 7.7 Abrocitinib* -- 7.8 Ruxolitinib* -- 7.9 Fedratinib* -- 7.10 Pacritinib* -- 7.11 Ritlecitinib# -- 7.12 Brepocitinib# -- 7.13 Ropsacitinib# -- Chapter 8. Allosteric TYK2 Inhibitors -- 8.1 Deucravacitinib* -- Chapter 9. ALK/multikinase Inhibitors -- 9.1 Crizotinib* -- 9.2 Ceritinib* -- 9.3 Alectinib* -- 9.4 Brigatinib* -- 9.5 Lorlatinib* -- Chapter 10. BRAF/Multikinase Inhibitors -- 10.1 Vemurafenib* -- 10.2 Dabrafenib* -- 10.3 Encorafenib* -- Chapter 11. MEK Inhibitors -- 11.1 Trametinib* -- 11.2 Cobimetinib*.

11.3 Binimetinib* -- 11.4 Selumetinib* -- Chapter 12. RET/Multikinase Inhibitors -- 12.1 Vandetanib* -- 12.2 Cabozantinib* -- 12.3 Selpercatinib* -- 12.4 Pralsetinib* -- Chapter 13. FGFR Inhibitors -- 13.1 Erdafitinib* -- 13.2 Pemigatinib* -- 13.3 Infigratinib* -- 13.4 Futibatinib* -- Chapter 14. PI3K Inhibitors -- 14.1 Alpelisib* -- 14.2 Idelalisib* -- 14.3 Duvelisib* -- 14.4 Umbralisib* -- 14.5 Copanlisib* -- Chapter 15. TRK/Multikinase Inhibitors -- 15.1 Larotrectinib* -- 15.2 Entrectinib* -- 15.3 Repotrectinib# -- Chapter 16. MET Inhibitors -- 16.1 Capmatinib* -- 16.2 Tepotinib* -- Chapter 17. KIT/PDGFR/Multkinase Inhibitors -- 17.1 Avapritinib* -- 17.2 Ripretinib* -- Chapter 18. FLT3 Inhibitors -- 18.1 Midostaurin* -- 18.2 Gilteritinib* -- Chapter 19. mTOR Inhibitors -- 19.1 Sirolimus* and Analogs -- Chapter 20. Other Kinase Inhibitors -- 20.1 Netarsudil* -- 20.2 Belumosudil* -- 20.3 Fostamatinib* -- 20.4 Pexidartinib* -- Chapter 21. KRAS Inhibitors -- 21.1 Sotorasib* -- 21.2 Adagrasib* -- 21.3 JDQ443# -- Chapter 22. An Overview of the Discovery Process for Medically Useful Inhibitors of Oncogenic Protein Kinases -- 22.1 High-quality Leads -- 22.2 Integrating Substructures from Different High Quality Leads or Established Inhibitors -- 22.3 Variation of Hinge-binding Nucleus -- 22.4 Macrocyclization -- 22.5 Fragment-based Approach -- 22.6 Covalent Inhibitors -- 22.7 Strategic Structural Modification of Prior Drugs -- 22.8 Exploiting Specific Kinase Pocket to Optimize Selectivity -- 22.9 Solvent-exposed Appendages to Enhance Solubility and PK Properties -- Chapter 23. Targeted Molecular Anticancer Therapies - Successes and Challenges -- 23.1 The Beginning -- 23.2 Further Developments -- 23.3 Biomarker-driven Drug Development -- 23.4 Mitigation of Drug Resistance -- 23.5 Miscellaneous Approaches -- 23.6 Discovery Chemistry.

Appendix 1. First FDA Approvals by Year -- Appendix 2. Kinase/KRAS Inhibitors in Development -- Appendix 3. Visualization of Differentially Expressed Kinases in Cancer -- Appendix 4. M &amp -- A Transactions Driven by Oncology-focused Kinase and KRAS Inhibitors -- Appendix 5. Alphabetic List of Oncogenic Protein Inhibitors -- EULA.

Sommario/riassunto

This book provides a comprehensive examination of recent scientific advancements in cancer treatment, focusing on the development of molecular therapies targeting oncogenic proteins. Authored by E. J. Corey and Yong-Jin Wu, it explores the transformation in cancer therapy over the last 30 years through the introduction of nearly 80 FDA-approved synthetic compounds. These compounds specifically target mutated biomolecules responsible for cancer, differing significantly from older cytotoxic agents. The book discusses the role of protein kinases, a class of enzymes integral to cell growth regulation, in cancer proliferation, and highlights the pivotal scientific research enabling these breakthroughs. It is intended for researchers, medical professionals, and students interested in oncology, molecular biology, and drug development.